Medical News

RSS

Affymetrix fourth quarter total revenue increases 2% to $84.4 million

Affymetrix, Inc., today reported its operating results for the three and twelve months ended December 31, 2012.

31 Jan 2013

FDA allows Arteriocyte to commence Magellan System Phase I trial in thermal burn wounds

Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan System technology in the treatment of thermal burn wounds.

31 Jan 2013

UnitedHealthcare launches UHC Research Institute

UHC is pleased to introduce the UHC Research Institute, an innovative program designed to provide the knowledge and insights its academic medical center (AMC) members need to lead the way in improving our nation's health care delivery system.

31 Jan 2013

DelMar announces second closing of $1.5M in private placement

DelMar Pharmaceuticals, Inc. today announced the second closing in a private placement consisting of approximately 1.9 million units of its securities to qualified accredited investors, for gross proceeds of approximately $1.5 million. The total amount raised in the private placement is $6.9 million.

31 Jan 2013

Velomedix commences rapid therapeutic hypothermia system pilot study in heart attack

Velomedix, a venture-backed medical device company advancing the field of therapeutic hypothermia, today announced the enrollment of the first patient in its VELOCITY pilot study.

31 Jan 2013

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

The U.S. Food and Drug Administration recently announced the authorization of FerriScan R2-MRI to be marketed as an imaging companion diagnostic device for the safe and effective use of Exjade in patients with non-transfusion-dependent thalassemia.

31 Jan 2013

Linden acquires Young Innovations

Young Innovations, Inc. today announced the completion of its acquisition by affiliates of Linden Capital Partners in an all-cash transaction valued at approximately $314 million.

31 Jan 2013

Study evaluates link between sedentary time and death among breast cancer survivors

Spending a lot of time watching television after breast cancer diagnosis is not linked to death in these breast cancer survivors. It appears that after accounting for self-reported physical activity levels after diagnosis, sedentary behavior was not an independent risk factor for death.

31 Jan 2013

Delaware District Court rules in favor of Pfizer in RAPAMUNE patent case

Pfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizer's patent covering a method for using sirolimus, the active ingredient in RAPAMUNE®, for the inhibition of organ transplant rejection is valid and infringed.

31 Jan 2013

McKesson third quarter revenues increase 1% to $31.2 billion

McKesson Corporation today reported that revenues for the third quarter ended December 31, 2012 were $31.2 billion, up 1% compared to $30.8 billion a year ago. On the basis of U.S. generally accepted accounting principles, third-quarter earnings per diluted share was $1.24 compared to $1.20 a year ago.

31 Jan 2013

Cerulean initiates CRLX101 Phase 2 study in extensive-stage small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy.

31 Jan 2013

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

CEL-SCI Corporation announced that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease.

31 Jan 2013

Oclaro second quarter revenues increase to $159.5 million

Oclaro, Inc., a provider of optical components, modules and subsystems, today announced the financial results for its second quarter of fiscal year 2013, which ended December 29, 2012.

31 Jan 2013

Nonin donates six Onyx 9500 finger pulse oximeters to Evangelistic International Ministries

Nonin Medical, Inc., the inventor of finger pulse oximeters and a leader in noninvasive medical monitoring, announced today that the company has donated six Onyx 9500 finger pulse oximeters to the Evangelistic International Ministries (EIM) for use at the Hospital Centro Socorro De Lo Alto in the remote village of Sula, Honduras.

31 Jan 2013

Adults should consume less than 5 g of salt and at least 3,510 mg of potassium per day: WHO

Adults should consume less than 2,000 mg of sodium, or 5 grams of salt, and at least 3,510 mg of potassium per day, according to new guidelines issued by the WHO. A person with either elevated sodium levels and low potassium levels could be at risk of raised blood pressure which increases the risk of heart disease and stroke.

31 Jan 2013

Abaxis third quarter revenues increase 32% to $49.8 million

Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the third fiscal quarter ended December 31, 2012.

31 Jan 2013

WHO releases resource package of practical tools to improve patient safety in hospitals

WHO released today a resource package of practical tools specifically aimed at improving patient safety in hospitals in developing countries.

31 Jan 2013

Positive results from PaxVax's Ad4-H5-Vtn vector vaccine Phase 1 trial on avian flu

PaxVax, Inc., which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced positive results in a Phase 1 clinical trial for its oral, replicating adenovirus serotype 4 (Ad4) vector vaccine for H5N1 (avian flu).

31 Jan 2013

Zimmer fourth quarter net sales increase to $1.18 billion

Zimmer Holdings, Inc. today reported financial results for the quarter and year ended December 31, 2012. The Company reported fourth quarter net sales of $1.18 billion, an increase of 1.1% reported and 2.1% constant currency over the fourth quarter of 2011.

31 Jan 2013

First Edition: January 31, 2013

Today's headlines include reports on a new health law final rule issued by the Internal Revenue Service eligibility and affordability standards for insurance subsidies.

31 Jan 2013

Medical News

Affymetrix fourth quarter total revenue increases 2% to $84.4 million

FDA allows Arteriocyte to commence Magellan System Phase I trial in thermal burn wounds

UnitedHealthcare launches UHC Research Institute

DelMar announces second closing of $1.5M in private placement

Velomedix commences rapid therapeutic hypothermia system pilot study in heart attack

Resonance Health receives FDA marketing authorization for FerriScan R2-MRI device

Linden acquires Young Innovations

Study evaluates link between sedentary time and death among breast cancer survivors

Delaware District Court rules in favor of Pfizer in RAPAMUNE patent case

McKesson third quarter revenues increase 1% to $31.2 billion

Cerulean initiates CRLX101 Phase 2 study in extensive-stage small cell lung cancer

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

Oclaro second quarter revenues increase to $159.5 million

Nonin donates six Onyx 9500 finger pulse oximeters to Evangelistic International Ministries

Adults should consume less than 5 g of salt and at least 3,510 mg of potassium per day: WHO

Abaxis third quarter revenues increase 32% to $49.8 million

WHO releases resource package of practical tools to improve patient safety in hospitals

Positive results from PaxVax's Ad4-H5-Vtn vector vaccine Phase 1 trial on avian flu

Zimmer fourth quarter net sales increase to $1.18 billion

First Edition: January 31, 2013

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

Latest News